ACCP 2024 Poster: Lorundrostat Concentration-QTc Results From the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect and Replaces the Thorough QT Study
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
AHA Scientific Sessions 2023 Poster: Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension
– An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension
ASN Kidney Week 2023 Poster: Identification of a Hypertensive Endotype with a Median Treatment Effect of -32 mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat
JAMA: Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension – The Target-HTN Randomized Clinical Trial
JAMA Editorial: A New Dawn for Aldosterone as a Therapeutic Target in Hypertension
AHA Hypertension 2023 Presentation: Target-HTN Trial on the Safety and Efficacy of Lorundrostat (MLS-101) in Patients With Uncontrolled Hypertension
ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor
ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation
